Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tailored supplement boost nutrition while preserving Parkinson's drug power?

NCT ID NCT06954662

Symptom relief Sponsor: UConn Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether a specialized amino acid supplement designed for people with Parkinson's disease can improve nutrition without interfering with their dopamine medication. Researchers will compare this supplement to a store-bought whey protein supplement and an inactive placebo. Participants, who are 55 or older and have been on stable dopamine medication for at least 3 months, will drink each supplement at separate visits. Blood samples will measure amino acid and levodopa levels, and researchers will also assess mood and movement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amino acid supplement and whey protein supplement
What this could lead to
If successful, this could point to a nutritional supplement that helps people with Parkinson's get better nutrition without reducing the effectiveness of their dopamine medication.
What could go wrong
This is a very early, small study with only 3 participants, so results may not apply broadly. The supplements could still interfere with medication absorption or cause digestive discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

3 people

The number who actually took part.

Started

May 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of idiopathic Parkinson disease by patient report * 55 years or older * Has been using dopamine replacement medication (e.g. levodopa) for at least 2 years. * On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months. Exclusion Criteria: * Apparent cognitive impairment as determined by phone screening (TICS) * Diagnosis of Parkinsonism or atypical Parkinson's Disease * Are prescribed a dopamine antagonist * Any unstable medical condition * Any known bleeding disorder or currently taking blood thinners * Using deep brain stimulation * Gastric or bowel resection surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease, idiopathic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease, idiopathic

Contacts and locations

Locations

  • UConn Health, Clinical Research Center

    Farmington, Connecticut, 06030-3805, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.